The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study

Yavuz, Mustafa; Yavuz, Aydın; Aydin, Faruk; Çan, Gamze; Kavgacı, Halil

doi:10.1016/s0360-3016(02)02870-5

Cited by 64 publications

(56 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our present study, both colonic and rectal mucosa demonstrated not only sstr2A immunoreactivity but also sstr1, 2B and 5 in the great majority of crypt cells of GI tract. Possible roles of somatostatin in intestinal tract are generally considered to include the suppression of chloride secretion [35,36] which is related to clinical treatment of octreotide for controlling secretory diarrhea [37][38][39].…”

Section: Discussionmentioning

confidence: 99%

Systemic Distribution of Somatostatin Receptor Subtypes in Human: An Immunohistochemical Study

et al. 2005

View full text Add to dashboard Cite

Abstract. Somatostatin is well known to inhibit the hormone secretion of various peptides. This action has been considered to be generally mediated via six different specific somatostatin receptors (sstr), sstr1, sstr2A, sstr2B, sstr3, sstr4, and sstr5. It then becomes very important to demonstrate the localization of these sstr subtypes in order to elucidate the possible biological and/or clinical significance of somatostatin actions. These sstr subtypes have been demonstrated to be expressed throughout the human body, including the central nervous system, gastrointestinal tract, pancreas, kidney, and other organs, but its details, especially its systemic distribution and localization in tissue compartments, have yet to be examined thoroughly in human. Therefore, in this study, we examined the systemic localization of all six somatostatin receptors in normal human organs using immunohistochemistry with recently developed specific antibodies against these receptor subtypes. In all of the human tissues examined, various sstr subtypes were detected not only in parenchymal cells but also in various stromal cells such as lymphocytes, fibroblasts, and endothelial cells. Among human tissues in which the presence of sstr has not been previously reported, the parotid gland demonstrated immunoreactivity for sstr2B and sstr5, bronchial gland for sstr1, 2B, 3, 4, 5, parathyroid gland for sstr1, 3, 4, and duodenum for all subtypes immunoreactivity. The great majority of other organs examined demonstrated results consistent with those of previously reported biochemical studies. In pancreatic islet cells, only sstr2A was positive in all the cases but other sstr subtypes were associated with marked intraislet heterogeneity in their distribution. In stomach, all subtypes of receptor were detected in various cell types of the mucosa, but none in ECL cells of fundic gland. These findings demonstrated the broad systemic actions of somatostatin in non-endocrine cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic Distribution of Somatostatin Receptor Subtypes in Human: An Immunohistochemical Study

et al. 2005

View full text Add to dashboard Cite

show abstract

“…for 5 d is apparently an effective, well-tolerated treatment modality for concurrent chemoradiotherapy-induced diarrhea refractory to loperamide [17] . Octreotide appears to be more effective than conventional therapy with diphenoxylate and atropine in controlling acute radiationinduced diarrhea and eliminating the need for radiotherapy interruptions [18] . Apart from anti-diarrheal medications, other measures of general management of acute radiation enteropathy include administration of antiemetics.…”

Section: Empirical-experimental Managementmentioning

confidence: 96%

Recent advances in the management of radiation colitis

Kountouras¹,

Zavos²

2008

WJG

View full text Add to dashboard Cite

show abstract

“…This is the main mechanism underlying the pathophysiology of acute radiation-induced enteritis and colitis, which are a common and potentially severe complication among cancer patients treated with radiation therapy. Attempts to treat this complication with antibiotics, sucralfate, antiinflammatory drugs such as mesalazine and balsalazide, glutamine, octreotide, proteolytic enzymes, and hyperbaric oxygen have so far provided inconclusive clinical results with failure of treatment occurring in a substantial proportion of patients [1][2][3][4][5][6][7][8][9] . Furthermore, prophylactic use of sucralfate does not reduce the burden of radiationinduced bowel toxicity but rather, is associated with more severe gastrointestinal symptoms including bleeding and fecal incontinence [10,11] .…”

Section: Introductionmentioning

confidence: 99%

Use of probiotics for prevention of radiation-induced diarrhea

Delia

Sansotta²,

Donato³

et al. 2007

WJG

252

235

View full text Add to dashboard Cite

AIM:To investigate the efficacy of a high-potency probiotic preparation on prevention of radiation-induced diarrhea in cancer patients. METHODS:This was a double-blind, placebo-controlled trial. Four hundred and ninety patients who underwent adjuvant postoperative radiation therapy after surgery for sigmoid, rectal, or cervical cancer were assigned to either the high-potency probiotic preparation VSL#3 (one sachet t.i.d. ,) or placebo starting from the first day of radiation therapy. Efficacy endpoints were incidence and severity of radiation-induced diarrhea, daily number of bowel movements, and the time from the start of the study to the use of loperamide as rescue medication. RESULTS:More placebo patients had radiation-induced diarrhea than VSL#3 patients (124 of 239 patients, 51.8%, and 77 of 243 patients, 31.6%; P < 0.001) and more patients given placebo suffered grade 3 or 4 diarrhea compared with VSL#3 recipients (55.4% and 1.4%, P < 0.001). Daily bowel movements were 14.7 ± 6 and 5.1 ± 3 among placebo and VSL#3 recipients (P < 0.05), and the mean time to the use of loperamide was 86 ± 6 h for placebo patients and 122 ± 8 h for VSL#3 patients (P < 0.001). CONCLUSION:Probiotic lactic acid-producing bacteria are an easy, safe, and feasible approach to protect cancer patients against the risk of radiation-induced diarrhea.

show abstract

The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study

Cited by 64 publications

References 46 publications

Systemic Distribution of Somatostatin Receptor Subtypes in Human: An Immunohistochemical Study

Systemic Distribution of Somatostatin Receptor Subtypes in Human: An Immunohistochemical Study

Recent advances in the management of radiation colitis

Use of probiotics for prevention of radiation-induced diarrhea

Contact Info

Product

Resources

About